NNAEMEKA O AGAJELU

Allopathic & Osteopathic Physicians|Internal Medicine GLEN BURNIE, MD NPI 1104891886

General Payments — all program years on this page

$5,193.04

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 222
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $463.85 across 17 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $463.8517

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Acerta Pharma LLC $229.765
Novo Nordisk AS $51.273
GlaxoSmithKline, LLC. $39.042
Astellas Pharma US Inc $38.682
ABBVIE INC. $37.792
PFIZER INC. $26.571
BOSTON SCIENTIFIC CORPORATION $20.891
Corcept Therapeutics $19.851

By program year

Program yearAmountRecords
2018 $560.6834
2019 $1,303.2047
2020 $615.5336
2021 $1,023.0146
2022 $719.4026
2023 $507.3716
2024 $463.8517

Records — PY2024 (17)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1092336223 Boston Scientific Corporation $20.89 11/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1096896545 Novo Nordisk Inc $15.99 02/01/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097038454 Novo Nordisk Inc $17.86 02/09/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097202585 Novo Nordisk Inc $17.42 06/21/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103178896 ABBVIE INC. $18.45 08/23/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1103178898 ABBVIE INC. $19.34 12/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104244479 AstraZeneca Pharmaceuticals LP $2.00 04/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1104579490 AstraZeneca Pharmaceuticals LP $21.27 04/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105660506 AstraZeneca Pharmaceuticals LP $86.22 03/06/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105684251 AstraZeneca Pharmaceuticals LP $98.54 04/24/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1105748615 AstraZeneca Pharmaceuticals LP $21.73 11/02/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116477108 GlaxoSmithKline, LLC. $23.50 01/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1116690441 GlaxoSmithKline, LLC. $15.54 05/17/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1117785537 Corcept Therapeutics $19.85 01/05/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1131962970 PFIZER INC. $26.57 09/13/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139305768 Astellas Pharma US Inc $17.76 03/29/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1139420825 Astellas Pharma US Inc $20.92 10/26/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.